Inve India ▾

Emami share price & results

Emami· Fast Moving Consumer Goods

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Kolkata-based FMCG maker of personal care and healthcare brands like Navratna, BoroPlus, Zandu and Kesh King.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue780 ₹ crore+3.2% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin28.0 %+1.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit182 ₹ crore+11.7% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity26.91 %−3.4 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin20.40 %−2.0 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)2.84 %−7.2 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

7 of 15 judged targets kept · 13 open · verdicts reflect calls analysed to Q1 FY27.

Emami management guidance track record on Inve: 28 targets tracked across analysed earnings calls (7 achieved, 8 missed, 13 open).

TargetOriginal wordingSaidLatest callVerdict
Investee Companies Portfolio Growth30% year-on-year
Call transcript, Q4 FY26 · 21 May 2026		Q4 FY26Q1 FY27:The strategic investment portfolio grew by an impressive 61% on a like-to-like basis in Q1 FY27, significantly exceeding the 30% YoY target.
Call transcript, Q1 FY27 · 4 Aug 2026		Achieved
Tax Rate8-9%
Call transcript, Q3 FY25 · 28 Jan 2025		Q3 FY25Q1 FY27:No new information provided on the final FY25 tax rate.
Call transcript, Q1 FY27 · 4 Aug 2026		Missed
Consolidated Effective Tax RateBelow 20%
Call transcript, Q3 FY26 · 4 Feb 2026		Q3 FY26Q1 FY27:Management revised the full-year tax rate guidance to 25-26%, a significant increase from the previous guidance of 'below 20%', citing the end of fiscal benefits.
Call transcript, Q1 FY27 · 4 Aug 2026		Revised Down

Source: Inve Guidance Tracker for Emami · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

8 of Emami's 28 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 25 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹368.9 +0.71% · +₹2.6

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance −32.3% 1Y

₹350₹400₹450₹500₹550Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 10 Nov 2025Q3 FY26 — 4 Feb 2026Q4 FY26 — 21 May 2026Q1 FY27 — 4 Aug 2026

1Y: ₹544.65 on 24 Oct 2025 → ₹368.9. High ₹550.6 (28 Oct 2025), low ₹363.65 (8 Sept 2026).

Previous close
₹366.3
Market cap
₹16.0k Cr
52-week range
₹363.65 – ₹550.6
One year
−32.29%
Price to earnings (TTM to Jun 2026)
21.15×
Return on equity (TTM to Jun 2026)
26.91%

Overview

Symbol
NSE:EMAMILTD
Exchange
NSE
Currency
INR

What Emami does

Based on the company's own presentations, annual report and earnings calls.

Emami Limited manufactures and markets personal care and healthcare products sold through a large retail and distributor network across India and international markets. It earns primarily through its domestic branded portfolio spanning pain management, healthcare, male grooming and hair-care categories, supplemented by international sales across SAARC, MENA, SEA, Africa and CIS regions. The company has grown its portfolio through acquisitions (Zandu Pharmaceutical Works, Kesh King, Creme 21, Dermicool) and strategic stakes in new-age FMCG and personal-care ventures such as The Man Company, Brillare, Axiom Ayurveda and IncNut.

Segments

  • Pain Management Range
  • Navratna & Dermicool Range
  • BoroPlus Range
  • Healthcare Range
  • Kesh King Range
  • Male Grooming Range
  • 7 Oils in One
  • The Man Company & Brillare
  • International Business
Retail outlets reached (India)
5.4 million+
Distributors (India)
3,400+
Countries with international presence
70
Product portfolio size
550+ products
Manufacturing factories
6 (including one overseas unit)
Regional offices
4
Founded 1974Headquarters Emami Tower, 687, Anandapur, EM Bypass, Kolkata 700107, West Bengal, India Company website

How the price took the results

close before → close after

Q1 FY27
−3.5%
4 Aug
Q4 FY26
−3.1%
21 May
Q3 FY26
+1.3%
4 Feb
Q2 FY26
+2.3%
10 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Emami

Free account: one company. Everything above stays public.

Write why you follow Emami and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Fast Moving Consumer Goods companies

All Fast Moving Consumer Goods companies → · Fast Moving Consumer Goods earnings growth →

Learn to analyse Emami

Guides on how to read this kind of business and the numbers that matter.